Skip to main content

HCPCS Level II

HCPCS Level II 2011 code changes

Every HCPCS Level II code whose CMS add date or termination date falls in 2011, grouped by effective date. Each code's own page carries its full record.

127
Added
0
Deleted

For HCPCS Level II, MedCoder records each code's CMS add date and termination date from the alpha-numeric file. A deletion is listed on the first day the code is no longer valid (the day after its CMS termination date). Description revisions between quarterly files are not recorded as changes.

Added effective January 1, 2011 (107)

  • A4566 — Shoulder sling or vest design, abduction restrainer, with or without swathe control, prefabricated, includes fitting and adjustment
  • A7020 — Interface for cough stimulating device, includes all components, replacement only
  • A9273 — Cold or hot fluid bottle, ice cap or collar, heat and/or cold wrap, any type
  • C9275 — Injection, hexaminolevulinate hydrochloride, 100 mg, per study dose
  • E0446 — Topical oxygen delivery system, not otherwise specified, includes all supplies and accessories
  • E1831 — Static progressive stretch toe device, extension and/or flexion, with or without range of motion adjustment, includes all components and accessories
  • E2622 — Skin protection wheelchair seat cushion, adjustable, width less than 22 inches, any depth
  • E2623 — Skin protection wheelchair seat cushion, adjustable, width 22 inches or greater, any depth
  • E2624 — Skin protection and positioning wheelchair seat cushion, adjustable, width less than 22 inches, any depth
  • E2625 — Skin protection and positioning wheelchair seat cushion, adjustable, width 22 inches or greater, any depth
  • G0157 — Services performed by a qualified physical therapist assistant in the home health or hospice setting, each 15 minutes
  • G0158 — Services performed by a qualified occupational therapist assistant in the home health or hospice setting, each 15 minutes
  • G0159 — Services performed by a qualified physical therapist, in the home health setting, in the establishment or delivery of a safe and effective physical therapy maintenance program, each 15 minutes
  • G0160 — Services performed by a qualified occupational therapist, in the home health setting, in the establishment or delivery of a safe and effective occupational therapy maintenance program, each 15 minutes
  • G0161 — Services performed by a qualified speech-language pathologist, in the home health setting, in the establishment or delivery of a safe and effective speech-language pathology maintenance program, each 15 minutes
  • G0162 — Skilled services by a registered nurse (rn) for management and evaluation of the plan of care; each 15 minutes (the patient's underlying condition or complication requires an rn to ensure that essential non-skilled care achieves its purpose in the home health or hospice setting)
  • G0163 — Skilled services of a licensed nurse (lpn or rn) for the observation and assessment of the patient's condition, each 15 minutes (the change in the patient's condition requires skilled nursing personnel to identify and evaluate the patient's need for possible modification of treatment in the home health or hospice setting)
  • G0164 — Skilled services of a licensed nurse (lpn or rn), in the training and/or education of a patient or family member, in the home health or hospice setting, each 15 minutes
  • G0434 — Drug screen, other than chromatographic; any number of drug classes, by clia waived test or moderate complexity test, per patient encounter
  • G0436 — Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes
  • G0437 — Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, greater than 10 minutes
  • G0438 — Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit
  • G0439 — Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit
  • G8629 — Documentation of order for prophylactic parenteral antibiotic to be given within one hour (if fluoroquinolone or vancomycin, two hours) prior to surgical incision (or start of procedure when no incision is required)
  • G8630 — Documentation that administration of prophylactic parenteral antibiotics was initiated within one hour (if fluoroquinolone or vancomycin, two hours) prior to surgical incision (or start of procedure when no incision is required), as ordered
  • G8631 — Clinician documented that patient was not an eligible candidate for ordering prophylactic parenteral antibiotics to be given within one hour (if fluoroquinolone or vancomycin, two hours) prior to surgical incision (or start of procedure when no incision is required)
  • G8632 — Prophylactic parenteral antibiotics were not ordered to be given or given within one hour (if fluoroquinolone or vancomycin, two hours) prior to the surgical incision (or start of procedure when no incision is required), reason not given
  • G8633 — Pharmacologic therapy (other than minerals/vitamins) for osteoporosis prescribed
  • G8634 — Clinician documented patient not an eligible candidate to receive pharmacologic therapy for osteoporosis
  • G8635 — Pharmacologic therapy for osteoporosis was not prescribed, reason not given
  • G8645 — I intend to report the asthma measures group
  • G8646 — All quality actions for the applicable measures in the asthma measures group have been performed for this patient
  • G8647 — Residual score for the knee impairment successfully calculated and the score was equal to zero (0) or greater than zero (> 0)
  • G8648 — Residual score for the knee impairment successfully calculated and the score was less than zero (< 0)
  • G8649 — Risk-adjusted functional status change residual score for the knee impairment not measured because the patient did not complete the fs status survey near discharge, patient not appropriate
  • G8650 — Residual score for the knee impairment not measured because the patient did not complete the lepf prom at initial evaluation and/or near discharge, reason not given
  • G8651 — Residual score for the hip impairment successfully calculated and the score was equal to zero (0) or greater than zero (> 0)
  • G8652 — Residual score for the hip impairment successfully calculated and the score was less than zero (< 0)
  • G8653 — Risk-adjusted functional status change residual scores for the hip impairment not measured because the patient did not complete the fs status survey near discharge, patient not appropriate
  • G8654 — Residual score for the hip impairment not measured because the patient did not complete the lepf prom at initial evaluation and/or near discharge, reason not given
  • G8655 — Residual score for the lower leg, foot or ankle impairment successfully calculated and the score was equal to zero (0) or greater than zero ( > 0)
  • G8656 — Residual score for the lower leg, foot or ankle impairment successfully calculated and the score was less than zero (< 0)
  • G8657 — Risk-adjusted functional status change residual score for the lower leg, foot or ankle impairment not measured because the patient did not complete the fs status survey near discharge, patient not appropriate
  • G8658 — Residual score for the lower leg, foot or ankle impairment not measured because the patient did not complete the lepf prom at initial evaluation and/or near discharge, reason not given
  • G8659 — Residual score for the low back impairment successfully calculated and the score was equal to zero (0) or greater than zero (> 0)
  • G8660 — Residual score for the low back impairment successfully calculated and the score was less than zero (< 0)
  • G8661 — Risk-adjusted functional status change residual score for the low back impairment not measured because the patient did not complete the fs status survey near discharge, patient not appropriate
  • G8662 — Residual score for the low back impairment not measured because the patient did not complete the low back fs prom at initial evaluation and/or near discharge, reason not given
  • G8663 — Residual score for the shoulder impairment successfully calculated and the score was equal to zero (0) or greater than zero (> 0)
  • G8664 — Residual score for the shoulder impairment successfully calculated and the score was less than zero (< 0)
  • G8665 — Risk-adjusted functional status change residual score for the shoulder impairment not measured because the patient did not complete the fs status survey near discharge, patient not appropriate
  • G8666 — Residual score for the shoulder impairment not measured because the patient did not complete the shoulder fs prom at initial evaluation and/or near discharge, reason not given
  • G8667 — Residual score for the elbow, wrist or hand impairment successfully calculated and the score was equal to zero (0) or greater than zero (> 0)
  • G8668 — Residual score for the elbow, wrist or hand impairment successfully calculated and the score was less than zero (< 0)
  • G8669 — Risk-adjusted functional status change residual score for the elbow, wrist or hand impairment not measured because the patient did not complete the fs status survey near discharge, patient not appropriate
  • G8670 — Residual score for the elbow, wrist or hand impairment not measured because the patient did not complete the elbow/wrist/hand fs prom at initial evaluation and/or near discharge, reason not given
  • G8671 — Risk-adjusted functional status change residual score for the neck, cranium, mandible, thoracic spine, ribs or other general orthopedic impairment successfully calculated and the score was equal to zero (0) or greater than zero (> 0)
  • G8672 — Risk-adjusted functional status change residual score for the neck, cranium, mandible, thoracic spine, ribs or other general orthopedic impairment successfully calculated and the score was less than zero (< 0)
  • G8673 — Risk-adjusted functional status change residual score for the neck, cranium, mandible, thoracic spine, ribs or other general orthopedic impairment not measured because the patient did not complete the fs status survey near discharge, patient not appropriate
  • G8674 — Risk-adjusted functional status change residual score for the neck, cranium, mandible, thoracic spine, ribs or other general orthopedic impairment not measured because the patient did not complete the general orthopedic fs prom at initial evaluation and/or near discharge, reason not given
  • G8682 — Lvf testing documented as being performed prior to discharge or in the previous 12 months
  • G8683 — Lvf testing not performed prior to discharge or in the previous 12 months for a medical or patient documented reason
  • G8685 — Lvf testing not documented as being performed prior to discharge or in the previous 12 months, reason not given
  • J0171 — Injection, adrenalin, epinephrine, 0.1 mg
  • J0558 — Injection, penicillin g benzathine and penicillin g procaine, 100,000 units
  • J0561 — Injection, penicillin g benzathine, 100,000 units
  • J0597 — Injection, c-1 esterase inhibitor (human), berinert, 10 units
  • J0638 — Injection, canakinumab, 1 mg
  • J0775 — Injection, collagenase, clostridium histolyticum, 0.01 mg
  • J1290 — Injection, ecallantide, 1 mg
  • J1559 — Injection, immune globulin (hizentra), 100 mg
  • J1599 — Injection, immune globulin, intravenous, non-lyophilized (e.g., liquid), not otherwise specified, 500 mg
  • J1786 — Injection, imiglucerase, 10 units
  • J1826 — Injection, interferon beta-1a, 30 mcg
  • J2358 — Injection, olanzapine, long-acting, 1 mg
  • J2426 — Injection, paliperidone palmitate extended release (invega sustenna), 1 mg
  • J3095 — Injection, telavancin, 10 mg
  • J3262 — Injection, tocilizumab, 1 mg
  • J3357 — Ustekinumab, for subcutaneous injection, 1 mg
  • J3385 — Injection, velaglucerase alfa, 100 units
  • J7196 — Injection, antithrombin recombinant, 50 i.u.
  • J7309 — Methyl aminolevulinate (mal) for topical administration, 16.8%, 1 gram
  • J7312 — Injection, dexamethasone, intravitreal implant, 0.1 mg
  • J7335 — Capsaicin 8% patch, per 10 square centimeters
  • J7686 — Treprostinil, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, 1.74 mg
  • J8562 — Fludarabine phosphate, oral, 10 mg
  • J9302 — Injection, ofatumumab, 10 mg
  • J9307 — Injection, pralatrexate, 1 mg
  • J9315 — Injection, romidepsin, 1 mg
  • J9351 — Injection, topotecan, 0.1 mg
  • L3674 — Shoulder orthosis, abduction positioning (airplane design), thoracic component and support bar, with or without nontorsion joint/turnbuckle, may include soft interface, straps, custom fabricated, includes fitting and adjustment
  • L4631 — Ankle foot orthosis, walking boot type, varus/valgus correction, rocker bottom, anterior tibial shell, soft interface, custom arch support, plastic or other material, includes straps and closures, custom fabricated
  • L5961 — Addition, endoskeletal system, polycentric hip joint, pneumatic or hydraulic control, rotation control, with or without flexion and/or extension control
  • L8693 — Auditory osseointegrated device abutment, any length, replacement only
  • Q0478 — Power adapter for use with electric or electric/pneumatic ventricular assist device, vehicle type
  • Q0479 — Power module for use with electric or electric/pneumatic ventricular assist device, replacement only
  • Q2035 — Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (afluria)
  • Q2036 — Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval)
  • Q2037 — Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin)
  • Q2038 — Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone)
  • Q2039 — Influenza virus vaccine, not otherwise specified
  • Q4117 — Hyalomatrix, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4118 — Matristem micromatrix, 1 mg
  • Q4119 — Matristem wound matrix, per square centimeter
  • Q4120 — Matristem burn matrix, per square centimeter
  • Q4121 — Theraskin, per square centimeter (add-on, list separately in addition to primary procedure)
  • T1505 — Electronic medication compliance management device, includes all components and accessories, not otherwise classified

Added effective July 1, 2011 (12)

  • C9285 — Lidocaine 70 mg/tetracaine 70 mg, per patch
  • G9148 — National committee for quality assurance - level 1 medical home
  • G9149 — National committee for quality assurance - level 2 medical home
  • G9150 — National committee for quality assurance - level 3 medical home
  • G9151 — Mapcp demonstration - state provided services
  • G9152 — Mapcp demonstration - community health teams
  • G9153 — Mapcp demonstration - physician incentive pool
  • K0743 — Suction pump, home model, portable, for use on wounds
  • K0744 — Absorptive wound dressing for use with suction pump, home model, portable, pad size 16 square inches or less
  • K0745 — Absorptive wound dressing for use with suction pump, home model, portable, pad size more than 16 square inches but less than or equal to 48 square inches
  • K0746 — Absorptive wound dressing for use with suction pump, home model, portable, pad size greater than 48 square inches
  • Q2043 — Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion

Added effective October 1, 2011 (2)

  • C1830 — Powered bone marrow biopsy needle
  • C1840 — Lens, intraocular (telescopic)

Added effective October 14, 2011 (3)

  • G0442 — Annual alcohol misuse screening, 5 to 15 minutes
  • G0443 — Brief face-to-face behavioral counseling for alcohol misuse, 15 minutes
  • G0444 — Annual depression screening, 5 to 15 minutes

Added effective November 8, 2011 (2)

  • G0445 — High intensity behavioral counseling to prevent sexually transmitted infection; face-to-face, individual, includes: education, skills training and guidance on how to change sexual behavior; performed semi-annually, 30 minutes
  • G0446 — Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes

Added effective November 29, 2011 (1)

  • G0447 — Face-to-face behavioral counseling for obesity, 15 minutes

Source: CMS HCPCS Level II alpha-numeric file (add and termination dates).

Source data

Source organization
CMS
Source release
HCPCS Level II October 2026 alpha-numeric file
Source file
october-2026-alpha-numeric-hcpcs-file.zip
File checksum (SHA-256)
c25240c63108756d4ba6c0ea785c517117d83bfed9526c51da8acf123de1feb6
Data read date
Data not available in the current MedCoder release record.
Effective date
CMS effective dates within 2011
Release type
Quarterly (January, April, July, October), with occasional mid-quarter additions
Methodology
Each code's add date and termination date are read from the alpha-numeric file. A deletion is dated the first day the code is no longer valid, the day after its termination date. Description revisions are not recorded as changes.

These changes are based on recorded release data. MedCoder does not generate coding changes with AI.

All releases in the Change Ledger